Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Natera, Inc.
  6. News
  7. Summary
    NTRA   US6323071042

NATERA, INC.

(NTRA)
  Report
Delayed Nasdaq  -  04:00:00 2023-03-30 pm EDT
54.26 USD   -4.64%
03/23New Publication Demonstrates Utility of Natera's Signatera Test in Melanoma
AQ
03/22New Publication Demonstrates Utility of Natera's Signatera™ Test in Melanoma
BU
03/13Natera, Inc. : Regulation FD Disclosure (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Natera, Inc. Announces Board Changes

01/25/2019 | 04:11pm EDT

On January 18, 2019, John Steuart resigned as a member of the Board of Directors of Natera, Inc., effective January 24, 2019. Mr. Steuart’s resignation was not a result of any disagreement with the Company on any matter relating to its operations, policies or practices. On January 24, 2019, the Board appointed Gail Marcus as Chair of the Audit Committee. Ms. Marcus joined the Board in March 2017 and currently serves as the Chair of the Nominating and Corporate Governance Committee.


© S&P Capital IQ 2019
All news about NATERA, INC.
03/23New Publication Demonstrates Utility of Natera's Signatera Test in Melanoma
AQ
03/22New Publication Demonstrates Utility of Natera's Signatera™ Test in Melanoma
BU
03/13Natera, Inc. : Regulation FD Disclosure (form 8-K)
AQ
03/08Transcript : Natera, Inc. Presents at Cowen 43rd Annual Healthcare Conference..
CI
03/07Transcript : Natera, Inc. Presents at Raymond James 44th Annual Institutional..
CI
03/06Insider Sell: Natera
MT
03/03Raymond James Raises Price Target on Natera to $68 From $58, Maintains Outperform Ratin..
MT
03/02Morgan Stanley Adjusts Natera Price Target to $72 From $70, Maintains Overweight Rating
MT
03/02Natera Announces Commercial Payor Coverage for Signatera™
BU
03/02Natera, Inc. Announces Commercial Payor Coverage for Signatera
CI
More news
Analyst Recommendations on NATERA, INC.
More recommendations
Financials (USD)
Sales 2023 990 M - -
Net income 2023 -454 M - -
Net cash 2023 211 M - -
P/E ratio 2023 -13,1x
Yield 2023 -
Capitalization 6 147 M 6 147 M -
EV / Sales 2023 6,00x
EV / Sales 2024 4,80x
Nbr of Employees 2 988
Free-Float 92,5%
Chart NATERA, INC.
Duration : Period :
Natera, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NATERA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 54,26 $
Average target price 75,43 $
Spread / Average Target 39,0%
EPS Revisions
Managers and Directors
Stephen Chapman Chief Commercial Officer
Michael Burkes Brophy Chief Financial & Accounting Officer
Matthew Rabinowitz President, Chief Executive Officer & Director
Eric A. Evans Chief Scientific Officer
Rishi Kacker Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
NATERA, INC.35.08%6 147
BIOMÉRIEUX-2.88%12 276
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.20.42%6 908
10X GENOMICS, INC.42.84%6 004
DIASORIN S.P.A.-24.51%5 731
LANTHEUS HOLDINGS, INC.58.40%5 505
Stock markets for all
100% Free Registration
fermer